أرسل هذا في رسالة قصيرة: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

__    __    _____    _    _      ___      ______  
\ \\ / //  |  ___|| | || | ||   / _ \\   /_   _// 
 \ \/ //   | ||__   | || | ||  / //\ \\    | ||   
  \  //    | ||__   | \\_/ || |  ___  ||  _| ||   
   \//     |_____||  \____//  |_||  |_|| /__//    
    `      `-----`    `---`   `-`   `-`  `--`